At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
Melatonin +1 moredrug
Likely dose
Melatonin 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Melatonin and Nighttime Blood Pressure in African Americans- 8 mg Study
In Brief
A Phase 2 clinical trial evaluating Melatonin and Placebo for Hypertension. Completed, enrolled 37 participants across 1 site.
Detailed Summary
This purpose of this study is to test the effect of oral melatonin supplementation (8 mg per night for 4 weeks) on nighttime blood pressure in African Americans with a history of elevated nighttime blood pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMay 2010
Primary CompletionSep 2013
Study CompletionSep 2014
TodayJul 2026
First PostedMay 3, 2010
Enrollment StartMar 1, 2010
Primary CompletionSep 1, 2013
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.2 years ago
Interventions
Melatonindrug
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
Placebodrug
Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.